Sermorelin
Sermorelin
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease. Purchasers must be 21 years or older. By purchasing, the buyer agrees to use these products in compliance with all applicable laws and regulations.
Sermorelin Overview
Sermorelin is a synthetic peptide analog of GHRH (1-29). It is studied in laboratory and preclinical models for its ability to modulate somatotroph axis signaling, thereby influencing downstream cascades and associated pathway activity. Research has focused on its role in endocrine modulation, molecular dynamics, and structural remodeling processes.
History
Sermorelin was developed in the late 20th century as a stabilized fragment of GHRH (1-29), the biologically active portion of the endogenous peptide. Initial investigations focused on its pharmacokinetics and ability to activate pituitary signaling pathways. Since then, it has been used widely in experimental models to study endocrine dynamics, pathway activity, and age-associated changes in somatotroph axis signaling.
Sermorelin Structure
Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight: 3357.9 g/mol
CAS: 86168-78-7
PubChem ID: 16132308
Research Findings
Sermorelin has been investigated in endocrine, signaling, and experimental models, with research focusing on its ability to modulate somatotroph axis activity, influence downstream cascades, and support structural remodeling mechanisms. Studies also highlight its role in pathway characterization, molecular proliferation, and signaling dynamics in preclinical settings.
Key Areas of Research:
- Endocrine: Somatotroph axis, signaling, cascades
- Signaling: Pathway dynamics, markers
- Molecular: Proliferation, remodeling, protein synthesis
Together, these findings suggest experimental utility for Sermorelin across multiple biological systems. By engaging endocrine signaling pathways and influencing downstream and remodeling processes, Sermorelin provides a platform for research into molecular dynamics, pathway characterization, and endocrine biology in laboratory settings.
References
Corpas, E., Harman, S.M., Piñeyro, M.A., Roberson, R., & Blackman, M.R. (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism, 75(2), 530–535.
Corpas, E., Harman, S.M., & Blackman, M.R. (1993). Human growth hormone and human aging. Endocrine Reviews, 14(1), 20–39.
Khorram, O., Laughlin, G.A., & Yen, S.S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479.